Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Accretive Health, Inc.    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Accretive Health, Inc. : Accretive Health Reports Inducement Grant under NYSE Rule 303A.08

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2013 | 01:05pm CET

Accretive Health, Inc. (NYSE: AH) today announced that pursuant to the employment agreement entered into with Stephen Schuckenbrock on April 2, 2013, the company granted to Mr. Schuckenbrock on April 3, 2013 a non-qualified stock option under the New York Stock Exchange inducement grant exception. The inducement grant was approved by the company's Board of Directors on April 1, 2013 and is being made as an inducement material to Mr. Schuckenbrock's acceptance of employment with the company, in accordance with New York Stock Exchange Rule 303A.08. The company previously announced that Mr. Schuckenbrock has been appointed President and Chief Executive Officer and a member of the company's Board of Directors, effective April 3, 2013.

The stock option is for the purchase of 2,903,801 shares of the company's common stock, with an exercise price of $9.56, which was the closing price of the company's common stock reported on the New York Stock Exchange on April 3, 2013. The stock option will vest and become exercisable on a ratable monthly basis over 48 months based on continued service to the company, subject to acceleration in specified circumstances.

Accretive Health is providing the above information regarding Mr. Schuckenbrock's inducement grant in accordance with New York Stock Exchange Rule 303A.08.

About Accretive Health

At Accretive Health, our mission is to help our healthcare clients strengthen their financial stability and deliver better care at a more affordable cost to the communities they serve (increasing healthcare access to all). For more information, visit www.accretivehealth.com.

Accretive Health, Inc.
Investor Relations:
Atif Rahim
Telephone: 312.324.5476
email: investorrelations@accretivehealth.com
or
Media:
Puneet Singh
Telephone: 330.565.6802
email: mediarelations@accretivehealth.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACCRETIVE HEALTH, INC.
01/10 R1 RCM INC. : Regulation FD Disclosure (form 8-K)
01/09 R1 RCM INC. (OTCMKTS : ACHI) Files An 8-K Amendments to Articles of Incorporatio..
01/05 R1 RCM INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, R..
01/05 ACCRETIVE HEALTH : Transforms into R1 RCM
2016 Accretive Health to Present at the 35th Annual J.P. Morgan Healthcare Confere..
2016 ACCRETIVE HEALTH, INC. (OTCMKTS : ACHI) Files An 8-K Departure of Directors or C..
2016 ACCRETIVE HEALTH, INC. : Change in Directors or Principal Officers, Submission o..
2016 ACCRETIVE HEALTH : Levels in Review for Accretive Health, Inc.
2016 ACCRETIVE HEALTH, INC. : Results of Operations and Financial Condition, Financia..
2016 ACCRETIVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
More news
Sector news : Ambulance & Emergency Services
01/13DJDAVITA : Judge Blocks Rule That Could Limit Premium Assistance for Dialysis Pati..
01/07DJFRESENIUS MEDICAL CARE : Impact Of Potential Regulation Change
2016 FTSE nudges higher though banks, Ashtead slide
2016DJQuest Diagnostics Reports Data Breach
2016DJUNIVERSAL HEALTH SERVICES : Denies Report of Filling Beds Solely for Financial G..
More sector news : Ambulance & Emergency Services
Advertisement
Financials ($)
Sales 2016 207 M
EBIT 2016 -36,3 M
Net income 2016 -
Finance 2016 20,6 M
Yield 2016 -
P/E ratio 2016 3,07
P/E ratio 2017
EV / Sales 2016 1,08x
EV / Sales 2017 0,56x
Capitalization 245 M
More Financials
Chart ACCRETIVE HEALTH, INC.
Duration : Period :
Accretive Health, Inc. Technical Analysis Chart | US00438V1035 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 3,75 $
Spread / Average Target 64%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Gerard Flanagan President, Chief Executive Officer & Director
Steve J. Shulman Chairman
Christopher Simon Ricaurte Chief Financial Officer & Treasurer
Alex J. Mandl Independent Director
Charles J. Ditkoff Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACCRETIVE HEALTH, INC.-12.68%245
FRESENIUS SE & CO KGAA-0.03%43 342
HCA HOLDINGS INC7.86%29 915
FRESENIUS MEDICAL CARE..-5.88%25 123
LABORATORY CORP. OF AM..3.24%13 652
QUEST DIAGNOSTICS INC-0.90%12 626
More Results